What has preoperative radio(chemo)therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients We asked what preoperative radiotherapy/chemoradiotherapy (PRT/PCRT) has brought to patients in terms of perioperative and long-term outcomes over the past decades. A systematic review and meta-analysis was conducted using PubMed, Embase and Web of Science databases. All original comparative studies published in English that were related to PRT/PCRT and surgical resection and which analyzed survival, postoperative and quality of life outcomes were included. Data synthesis and statistical analysis were carried out using Stata software. Data from 106 comparative studies based on 80 different trials enrolling 41,121 patients were included in our study. Based on our overall analyses, PRT/PCRT significantly improved patients' local recurrence-free survival (LRFS), but neither overall survival (OS) nor metastasis-free survival (MFS) showed improvement. In addition, PRT significantly increased the postoperative morbidity and mortality but PCRT did not have a significant effect. Furthermore, PRT/PCRT significantly increased the risk of postoperative wound complications but not anastomotic leakage and bowel obstruction. Our comprehensive subgroup analyses further supported the aforementioned results. Meanwhile, long-term anorectal symptoms (impaired squeeze pressures, use of pads, incontinence and urgency) and erectile dysfunction were also significantly increased in patients after PRT/PCRT. The benefits of PRT/PCRT as applied over the last several decades have not been sufficient to improve OS. Metastases of primary tumor and postoperative adverse effects were the two primary obstacles for an improved OS. In fact, the greatest advantage of PRT/PCRT is still local tumor control and a significantly improved LRFS.
Cancer Data Base, and further suggested that delivery of current preoperative regimens might be suboptimal. 4, 5 In addition to socioeconomic considerations, we need to determine if there is still an advantage in the use of preoperative radio(-chemo)therapy (PRT/PCRT) or if further improvement in survival outcomes can be obtained, since the greatest benefit of PRT/PCRT is local recurrence control based on results of well-known random control trials (RCTs; SRCT, TME, FFCD9201, EORTC22912 and TROG 01.04 trials [6] [7] [8] [9] [10] ) irrespective of the patterns or combinations of radiotherapy and chemotherapy. In addition, potentially adverse postoperative effects and quality of life outcomes should be taken into consideration when comprehensively evaluating the role of PRT/ PCRT. [11] [12] [13] [14] [15] Therefore, in this systematic review and meta-analysis we have summarized and re-evaluated the role of PRT/PCRT and also examined current neoadjuvant regimens for effectiveness in treating localized rectal cancer patients. Our goal was to determine what benefits PRT/PCRT has brought to localized rectal cancer patients in terms of perioperative and long-term outcomes. In addition, based on the relative merits of current neoadjuvant therapy, we discuss the future evolution of neoadjuvant regimens.
Methods

Search strategy
This systematic review and meta-analysis were conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (http://www.prisma-statement.org/). 16 A comprehensive search was performed to identify all relevant studies (restricted to the English language) in thePubMed, Embaseand Web of Sciences databases (up to September 2015). In addition, we formulated our search strategy based on the MeSH/main keywords of "rectal," "neoadjuvant," "preoperative," "preoperatively," "radiotherapy," "irradiation," "radiation," "chemotherapy," "chemoradiotherapy," "radiochemotherapy" and "chemoradiation" to collect all possible studies and avoid potential omissions. Furthermore, to avoid redundant studies, we checked all authors and organizations and evaluated the recruitment period and population of patients enrolled in each study. For multiple studies that were published using the same patient population based on the same outcomes, we only included the most informative study. If multiple studies reported different outcomes based on the same patient population, we combined their results for a more comprehensive analysis. For multiple-arms comparative studies, we only extracted data from the arms that matched our eligibility criteria. Finally, the lists of references in the relevant studies were also screened for additional studies.
Eligibility criteria
Eligible studies which met the following PICOS criteria (population, intervention, comparison, outcomes and study design) were enrolled in our systematic review and metaanalysis. (i) Population: patients definitely diagnosed with localized rectal cancer; (ii) Intervention: PRT or PCRT; (iii) Comparison: rectal cancer patients with PRT/PCRT in the experimental group versus patients without preoperative treatment in the control group; (iv) Outcomes: for primary endpoints, overall survival (OS), disease-free survival (DFS), cancer specific-survival (CSS), local recurrence-free survival (LRFS) and metastasis-free survival (MFS); for secondary endpoints, postoperative complications, mortality and quality of life outcomes; (v) Study design: comparative studies based on with and without PRT/PCRT rectal cancer patients. Studies were excluded from our systematic review and metaanalysis based on the following exclusion criteria: (i) studies which enrolled patients diagnosed with anal, colon/rectosigmoid cancer, colorectal metastases or recurrent rectal cancer; (ii) studies in which the experimental group was treated with intratumoral injections, intraoperative radiotherapy, endorectal brachytherapy or hyperthermia based on PRT/PCRT; (iii) studies which compared preoperative therapy versus postoperative therapy; (iv) studies with insufficient data (abstracts or meeting conferences) to extract for final quantitative analysis; (v) reviews and meta-analyses; (vi) studies with clinical outcomes not relevant to the present study.
Data extraction and study quality assessment
Three reviewers (Bin Ma, Hongchi Wang and Qingzhou Xu) reviewed and assessed each of the included studies. In addition, data extraction was performed completely independently. Extraction information consistent among the reviewers were used for our final analyses and disagreements between the reviewers were discussed with a fourth reviewer (Peng Gao) to reach a final consensus. Relevant data extracted from the eligible studies included (i) patient numbers; (ii) patient age; (iii) gender; (iv) whether or not the patient received postoperative chemotherapy; (v) Inclusion
What's new? Although preoperative radiotherapy/chemoradiotherapy (PRT/PCRT) is the standard neoadjuvant therapy for locally advanced rectal cancer, what it has brought to patients in terms of survival, postoperative, and quality of life outcomes is still controversial.
Here, the authors comprehensively analyze the advantages and adverse effects of PRT/PCRT in a large patient number. They found that the greatest advantages of PRT/PCRT remain local tumor control and significantly improved local recurrencefree survival. The benefits of PRT/PCRT as applied over the last several decades have not been sufficient to improve overall survival, however, with metastases and postoperative adverse effects being the two primary obstacles.
criterion; (vi) tumor location (distance from tumor to anal verge); (vii) sphincter preservation rate; (viii) study quality assessment; (ix) publication year; (x) study period; (xi) country; (xii) study design; (xiii) comparative study type; (xiv) PRT/PCRT regimens; (xv) interval (duration between completion of PRT/PCRT and surgery); (xvi) follow-up; and (xvii) outcomes including survival outcomes (OS, DFS, CSS, LRFS and MFS), postoperative outcomes (wound complications, anastomotic leakage, bowel obstruction, total morbidity and total mortality) and quality of life outcomes (anorectal, gastrointestinal, urinary and sexual). The Newcastle-Ottawa Scale (NOS) criterion recommended by the Cochrane Library for included trials was used to evaluate the quality of included studies. 17 
Statistical methods
In our systematic review and meta-analysis, the most appropriate statistic to use for evaluating primary endpoints (timeto-event outcomes) was the hazard ratio (HR). If studies did not provide the HR directly, we obtained an estimated HR by methods designed by Tierney 18 using the Kaplan-Meier curve or the p values of the log-rank test and the number of observed events in each group. In addition, we used the odds ratio (OR) and the weighted mean difference (WMD) to evaluate dichotomous and continuous variables, respectively, for secondary endpoints (postoperative and quality of life outcomes).
We conducted overall meta-analyses for comparisons between rectal cancer patients with and without PRT/PCRT. In addition, we performed subgroup analyses based on (i) study design, (ii) study period and follow-up, (iii) patient median age, (iv) tumor location, (v) population regions, (vi) regimens of preoperative treatment, (vii) surgical type and technique, (viii) pathologic stage and (ix) postoperative adjuvant therapy to provide comprehensive analyses in terms of survival and postoperative outcomes. Furthermore, univariate meta-regression analyses of random effects were conducted to investigate the origin of existing heterogeneity based on the above aspects. 19 Finally, publication bias was assessed using Begg's and Egger's tests. 20, 21 All analyses were performed using Stata software, version 12.0 (2011; Stata Corp., College Station, TX). All the analyses in this study used a random-effects model because it provided more conservative estimates and was tailored to multicenter studies in which heterogeneity was usually present. 22 All statistical values were reported with the 95% confidence interval (CI) and a two-tailed p values <0.05 was defined as statistical significance.
Results
Study search and characteristics of included studies
The detailed steps of our search for studies are shown in Figure 1 . After removing duplicates, screening the titles and abstracts, and further evaluating the context of the studies, data from 106 studies based on 80 different comparative studies (RCTs 5 14, retrospective comparative studies 5 49, prospective comparative studies 5 17) were finally included in our systematic review and meta-analysis (Supporting Information references). A total of 41,121 rectal cancer patients were enrolled (treatment group 5 17,078 patients; Cancer Therapy and Prevention control group 5 24,043 patients). Among the included studies, 44 studies were from European countries, 20 studies were from Asian countries and 15 studies were from American countries (including North and South America), and one study was conducted in Australia. For study period and follow-up, 55 studies selected patients diagnosed after 1990 and 22 studies had a median follow-up longer than 60 months. Following the NOS criterion, 36 studies were evaluated as high-quality, 37 studies were moderate-quality and seven studies were low-quality.
Detailed characteristics of the included studies are shown in Supporting Information Tables S1 and S2. PRT was used in 36 studies and PCRT was used in 46 studies (Two studies had three arms including PRT, PCRT and surgery alone). For studies of PRT, patients enrolled were generally those with resectable rectal cancer, whereas patients receiving PCRT were usually those with tumors in clinical stage II/III. Regimens of PRT primarily included short-course radiotherapy with immediate surgery or long-course radiotherapy with delayed surgery. Regimens of PCRT were mainly based on long-course radiotherapy with concomitant chemotherapy using 5-fluorouracil. Furthermore, in 23 studies postoperative adjuvant chemotherapy was delivered to both groups. Regarding tumor location, 20 studies did not provide a definitive distance between tumor and anal verge, but the remaining studies selected patients with tumors located below 16 cm and up to the anal verge. Finally, data based on 45 different studies were used for survival outcomes metaanalyses, 53 different studies were used for postoperative outcomes meta-analyses and 20 different studies were used for quality of life outcomes meta-analyses. Table 1 for PRT and Table 2 for PCRT. Table 1 ). Furthermore, PCRT in subgroups of American populations also showed significant benefit to DFS (HR 5 0.74, 95% CI 5 0.56-0.97, p 5 0.03; Table 2 ).
CSS after PRT and PCRT. From our results, a significantly improved CSS was observed in patients receiving PRT but not PCRT (PRT: HR 5 0.75, 95% CI 5 0.65-0.86, p < 0.01; PCRT: HR 5 0.71, 95% CI 5 0.43-1.17, p 5 0.18). Moreover, all the applicable subgroups of PRT showed a similar benefit (Tables 1 and 2 ). However, although only the subgroup of PCRT based on a follow-up of 60 months or longer showed a statistically significant benefit to CSS (HR 5 0.47, 95% CI 5 0.23-0.96, p 5 0.04), results of other subgroup analyses showed a consistent tendency towards improved CSS in patients receiving PCRT ( Table 2) . (Tables 1 and 2 ).
Postoperative outcomes after PRT and PCRT Postoperative wound complications, anastomotic leakage and bowel obstruction after PRT and PCRT. Wound complications (infection, abscess and sepsis), anastomotic leakage and bowel obstruction were the most frequent and serious postoperative complications after rectal cancer resection. Our pooled analyses indicated that PRT and PCRT significantly increased the incidence of wound problems (PRT: OR 5 1.43, 95% CI 5 1.17-1.74, p < 0.01; PCRT: OR 5 1.52, 95% CI 5 1.08-2.16, p 5 0.02) but not the incidence of anastomotic leakage or bowel obstruction. In addition, all subgroup analyses showed an increasing tendency of postoperative wound problems after PRT or PCRT (Table 3) Cancer Therapy and Prevention Table 2 . Meta-analyses of survival outcomes of PCRT Table 4 .
Meta-regression analyses and publication bias
Based on the results of our meta-regression analyses (Supporting Information Table S3 ), we found that study period, study design, follow-up time, population, clinical stage, tumor location, treatment regimen and patient age did not contribute to heterogeneity of OS based on either PRT or PCRT. In addition, Begg's and Egger's tests both indicated that there was no publication bias between studies based on OS (Begg's test: p 5 0.82; Egger's test: p 5 0.58; Supporting Information Fig. S1 ).
Discussion
In recent decades, clinicians throughout the world have tried to optimize the sequence and combination of radiotherapy, chemotherapy and surgery for cancer patients. Although PRT/PCRT has been used as the standard neoadjuvant therapy for LARC patients, acceptance of this standard is still being debated. [23] [24] [25] Notably, although the use of neoadjuvant therapy has increased during the last decade, >40% of patients still did not receive any form of neoadjuvant therapy from 2010 to 2012 in the United States alone. 4, 5 This situation led us to reconsider whether limited survival outcomes for rectal cancer, especially OS, could be improved. We further questioned if, in addition to the increased toxicities, postoperative and quality of life outcomes were adversely affected by adding PRT/PCRT. After taking all these factors into consideration, the most important issue for us was to determine what benefit PRT/PCRT has brought to LARC patients over the past several decades and whether the current regimen of neoadjuvant therapy is still appropriate for rectal cancer patients. The primary effect of PRT/PCRT is the sterilization of local primary tumor cells and prevention of regional tumor cell deposits to diminish the risk of a loco-regional recurrence. 26 These effects are consistent with our result showing an improvement in LRFS in patients receiving PRT/PCRT. In addition, disease progression and cancer-specific death caused by tumor recurrence maybe partly decreased by PRT/PCRT. However, whether PRT/PCRT could improve OS has remained controversial. 6, 7 Based on our results, all of our subgroup analyses showed that PRT/PCRT were not associated with increased OS except for a subgroup of American patients receiving PCRT; however, the limited number of studies (n 5 2) and observational data restrict the conclusions that can be drawn from this subgroup. In fact, the biggest problem with current therapies, based on our results and previous evidence, 27 remains uncontrolled metastases of the primary tumor. Furthermore, the increased postoperative mortality of the PRT regimen and acute III-IV toxicities of PCRT counter the advantage of improved LRFS. 28 Therefore, we believe that the advantage of PRT/PCRT in tumor recurrence control may be insufficient to contribute to an improvement in OS. Postoperative and quality of life outcomes are important factors which should be taken into consideration by surgeons in evaluating the role of PRT/PCRT. Neoadjuvant radiotherapy may increase wound problems and reduce wound healing because it damages DNA and proteins, which could lead to apoptotic cell death. 29 Radiotherapy may also affect proinflammatory cytokines in the early phase of treatment, 29 resulting in inadequate resolution of inflammation that may lead to uncontrolled matrix accumulation and fibrosis. In addition, decreased levels of nitric oxide and matrix metalloproteinase may contribute to inadequate soft tissue reconstruction. 30, 31 These reasons might explain why PRT/PCRT increased the incidence of postoperative wound complications (infection, abscess and sepsis). In addition, recent research has also shown that PRT/PCRT were not associated with postoperative anastomotic leakage and bowel obstruction, [32] [33] [34] which is consistent with our results. Notably, in comparison to PCRT, PRT increased postoperative total morbidity and mortality in our results, which was verified in subgroups of patients receiving a radiotherapy regimen of five fractions or less and in patients at a median age of 65 or older. The Stockholm III trial had indicated that short-course radiotherapy (25 Gy, five fractions) with immediate surgery showed the highest rate of impaired postoperative leukocyte response and total morbidity in comparison with short-course or longcourse radiotherapy with delayed surgery. 35, 36 In agreement, our results indicated that short-course PRT with a dose over 5 Gy in every fraction increased postoperative risks in comparison to long-course PCRT with only 1.8 Gy in every fraction. Furthermore, our long-term results emphasize that the risk of anorectal dysfunction after preoperative treatment should be communicated to patients. For rectal cancer patients, surgeons should increase awareness of both oncological as well as long-term functional outcomes. 37 According to our results of PRT/PCRT in terms of perioperative and long-term outcomes, metastases of the primary tumor and postoperative adverse effects were the primary two barriers to an improved OS. Therefore, simplified and optimized therapies which could maintain the present advantages of PRT/PCRT, further improve MFS and decrease adverse effects should be developed. Regarding metastases, the latest evidence suggests that adding oxaliplatin could significantly decrease the distant metastasis rate but may also increase acute III-IV toxicities in comparison with fluorouracil-based neoadjuvant chemoradiotherapy. 38 In addition, administering chemotherapy at an earlier point might decrease micrometastases and reduce the incidence of distant metastases. 39 Thus, induction chemotherapy followed by PCRT may achieve the full advantage of systemic chemotherapy. Published randomized phase II trials in Spain and Belgium have reported promising results for induction chemotherapy compared with conventional PCRT. 40, 41 Furthermore, systemic chemotherapy alone without radiotherapy may not only reduce the risk of distant metastases 24 but also decrease the toxicities and postoperative complications caused by radiotherapy. Notably, the FOWARC randomized phase III trial has published its initial results using modified FOLFOX6 with and without radiation versus fluorouracil and leucovorin with radiation for LARC. 42 This trial indicated that preoperative mFOLFOX6 alone had less toxicity and fewer postoperative complications. 42 In the future, long-term survival outcomes of the FOWARC trial and the ongoing phase III PROSPECT trials (NCCTC N1048) may determine if preoperative chemotherapy alone could be an alternative choice for LARC patients. Another optimized regimen for decreasing postoperative adverse effects is shortcourse radiotherapy with delayed surgery, as shown in the latest Stockholm III results. 43 In summary, these research studies have provided evidence for simplifying and optimizing current therapies, but additional phase III RCTs will need to be conducted in order to further verify the feasibility and safety of these regimens.
Another strategy for improving outcomes of LARC patients is selecting the subgroup population which would most benefit from current neoadjuvant therapy. However, we were unable to definitively identify a beneficial population based on the clinical information in our included studies. Acquisition of more comprehensive clinical and molecular information may be a potential method to select the population most benefiting from treatment. Presumably, patients who could achieve a pathological complete response (pCR) would most benefit from neoadjuvant therapy. Therefore, a more robust examination of factors responding to neoadjuvant therapy, including clinical and molecular markers of pCR, may be necessary to develop more personalized and precise treatments. Previous studies have indicated that a low pretreatment of carcino-embryonic antigen ( 5 mg/mL) was significantly associated with pCR. [44] [45] [46] Furthermore, although none of the molecular biomarkers studied to date have been approved for clinical practice, novel next-generation sequencing analysis and microarray techniques provide the possibility of more precise treatment in the neoadjuvant era. We therefore hope that in the near future, combination analysis based on clinical and molecular markers may further stratify and select patients who are the most appropriate candidates for neoadjuvant therapy.
In summary, the most important result of our study was to comprehensively and quantitatively indicate the advantages and adverse effects of PRT/PCRT with an extremely large patient number. We also took postoperative and long-term quality of life outcomes into consideration to analyze whether PRT/PCRT could improve patients' survival outcomes, especially OS. Finally, based on our quantitative results, we have provided objective evidence for guiding the future evolution of neoadjuvant treatment in LARC patients. There were, however, some limitations to our systematic review and meta-analysis. Although we tried to conduct comprehensive subgroup analyses based on the included studies, we were unable to analyze by all possible methods some critical factors such as clinical T or N or TNM stage. The main impediment was the lack of individual original data from the included studies, which limited the subgroup analyses that could be conducted. In addition, numerous methodological and reporting inconsistencies among the included studies also restricted our ability to conduct these subgroup analyses: (i) retrospective studies mainly enrolled patients with pathological staging but did not provide initial stage; (ii) the study of Park et al. (Supporting Information Ref. 105 ) selected patients with only clinical T3N0M0 rectal cancer patients, while all other studies with survival outcomes enrolled a mixed patient population; and (iii) no included studies with a mixed patient population provided a detailed data of survival outcomes stratified by initial staging. In addition, recent studies have indicated that postoperative adjuvant chemotherapy might improve survival outcomes for a subgroup of rectal cancer patients after neoadjuvant treatment, 47, 48 but it is unknown if postoperative chemotherapy and the completion rate may have biased our overall and subgroup analyses based on survival outcomes. Finally, while we have demonstrated an overall trend for the advantages and potential adverse effects of PRT/PCRT based on present data, we still could not identify which patient subgroups would definitely benefit from current neoadjuvant regimens, especially with improved OS. Hence, we will try to collect individual data to further explore these issues in our future investigations.
Conclusions
Despite several decades experience in treating patients, the benefit of PRT/PCRT for improving OS in rectal cancer has still not been clearly demonstrated. Actually, the greatest advantage of PRT/PCRT remains local tumor control and a significant improvement in LRFS has been observed. Metastases of the primary tumor and postoperative adverse effects have been the primary obstacles for improving OS with PRT/ PCRT. Therefore, optimized therapies that could maintain present outcomes, further improve MFS and decrease adverse effects need to be explored. Furthermore, although comprehensive subgroup analyses were conducted, we were unable to definitively identify specific populations benefiting from current PRT/PCRT regimens. Personalized and precise treatments based on clinical and molecular factors may thus be the future direction of neoadjuvant therapy.
